Engineered Peptide ARA290 Protects Cells from Doxorubicin Chemotherapy Toxicity

Doxorubicin is a powerful chemotherapy agent widely used to treat various cancers, but its clinical utility is severely hampered by dose-limiting side effects, particularly cardiotoxicity and genotoxicity (damage to cellular DNA). These adverse effects are largely attributed to the induction of oxidative stress within healthy cells. Current strategies to mitigate these toxicities often compromise the drug's anti-cancer efficacy, highlighting an urgent need for novel protective therapies. This study aimed to investigate whether the engineered erythropoietin-derived peptide, ARA290, could attenuate doxorubicin-induced genotoxicity and oxidative stress in an in vitro model.

Exposure to doxorubicin alone resulted in a significant increase in both DNA damage and markers of oxidative stress within the human lymphocyte cells. Crucially, pre-treatment with ARA290 demonstrated a dose-dependent and significant attenuation of these detrimental effects. > The most striking finding was that the highest concentration of ARA290 (100 nM) effectively reduced doxorubicin-induced DNA damage by a remarkable 43% (p<0.001) compared to cells treated with doxorubicin alone. Furthermore, ARA290 at 100 nM significantly decreased levels of malondialdehyde (MDA), a key biomarker of lipid peroxidation and oxidative damage, by 35% (p<0.01). Concurrently, the peptide enhanced the total antioxidant capacity (TAC) of the cells by 28% (p<0.05) at the same concentration, indicating a bolstered intrinsic defense against reactive oxygen species. These robust protective effects were consistently observed across the range of ARA290 concentrations tested, confirming its efficacy in mitigating doxorubicin's cellular toxicity.